Maintenance

Ongoing treatment given after a flare has settled, to keep the disease quiet and stop it coming back.

Also called: maintenance therapy, maintenance phase

Related words induction maintenance of remission

Topics Research Medicines

Where to read more

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

British Society of Gastroenterology Guideline Jun 2025 For professionals

The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.

Topics About Crohn's disease Diagnosis and tests Medicines Monitoring Complications Surgery

Jargon explained Montreal classification remission endoscopic remission inflammatory bowel disease advanced therapy GRADE induction maintenance

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH)

Gastroenterology Study Mar 2007 Patients and professionals

The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.

Topics Children and young people Biologics and newer medicines

Jargon explained induction maintenance clinical response PCDAI

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

The Lancet Study May 2002 Patients and professionals

This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.

Topics Biologics and newer medicines Research

Jargon explained maintenance therapy remission placebo

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)

New England Journal of Medicine Study Nov 2016 Patients and professionals

The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.

Topics Biologics and newer medicines

Jargon explained induction maintenance IL-12/23 placebo

Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2)

New England Journal of Medicine Study Aug 2013 Patients and professionals

The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.

Topics Biologics and newer medicines

Jargon explained integrin induction maintenance serious adverse event

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

Antibiotics for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Feb 2019 Patients and professionals

Antibiotics may give a small benefit for active Crohn's, but probably not enough to make a real difference for most people. They did not cause more side effects than placebo. Whether they help keep Crohn's in remission is unclear. Note this is about treating the Crohn's itself, not infections or abscesses.

Topics Medicines Research

Jargon explained antibiotic clinically meaningful antibiotics induction maintenance

Vedolizumab for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Jul 2023 Patients and professionals

Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.

Topics Biologics and newer medicines Research

Jargon explained high-certainty evidence induction maintenance integrin

Search everything for "maintenance"